Advanced Cancer

Oncology
73
Pipeline Programs
30
Companies
50
Clinical Trials
9 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
59
12
1
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
563%
Monoclonal Antibody
338%
+ 68 programs with unclassified modality

Competitive Landscape

33 companies ranked by most advanced pipeline stage

AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
3 programs
2
1
T-DXdPhase 3
AZD2171Phase 11 trial
olaparibPhase 11 trial
Active Trials
NCT00621725Completed36Est. Jan 2014
NCT02338622Completed60Est. Mar 2017
Alliance Pharmaceuticals
1 program
1
RemeronPhase 21 trial
Active Trials
NCT00832520Terminated13Est. Jun 2011
CT
17 programs
16
1
TQB2858 injectionPhase 1/21 trial
AL2846Phase 11 trial
AnlotinibPhase 1Small Molecule1 trial
SinoteceanPhase 11 trial
TQ-B3101Phase 11 trial
+12 more programs
Active Trials
NCT02779699UnknownEst. Oct 2020
NCT02825563CompletedEst. Aug 2018
NCT02469883UnknownEst. Dec 2016
+14 more trials
Bristol Myers Squibb
7 programs
3
3
BMS-986258Phase 1/21 trial
IpilimumabPhase 1/2Monoclonal Antibody1 trial
NivolumabPhase 1/2Monoclonal Antibody
BMS-986148Phase 11 trial
BMS-986205Phase 11 trial
+2 more programs
Active Trials
NCT05162443Approved For Marketing
NCT02884726Completed8Est. Sep 2017
NCT03192943Completed11Est. Dec 2018
+3 more trials
M&
Merck & Co.RAHWAY, NJ
5 programs
3
2
LY3200882Phase 1/21 trial
TT-816Phase 1/21 trial
ASTX660Phase 11 trial
FS120Phase 11 trial
MK2461Phase 11 trial
Active Trials
NCT05082259Recruiting61Est. Mar 2026
NCT04648202Active Not Recruiting82Est. Mar 2026
NCT00518739Completed25Est. Dec 2008
+2 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
4 programs
3
1
LY3200882Phase 1/2
LY3023414Phase 11 trial
LY900009 - Dose Escalation PhasePhase 11 trial
[¹⁴C]PrexasertibPhase 1Small Molecule1 trial
Active Trials
NCT01655225Completed156Est. Feb 2022
NCT01158404Completed35Est. Aug 2012
NCT02778126Completed6Est. Jul 2017
CASI Pharmaceuticals
CASI PharmaceuticalsBEIJING, China
3 programs
2
1
MKC-1Phase 1/21 trial
ENMD-2076Phase 11 trial
MKC-1Phase 11 trial
Active Trials
NCT00658671CompletedEst. Jun 2012
NCT00656461CompletedEst. Nov 2009
NCT00408226CompletedEst. Jan 2012
Artios Pharma
Artios PharmaUK - Cambridge
2 programs
1
1
ART0380Phase 1/21 trial
ART4215Phase 11 trial
Active Trials
NCT04991480Completed93Est. Dec 2025
NCT04657068Recruiting502Est. Dec 2026
FP
Fosun PharmaAustralia - Sydney
2 programs
1
1
SAF-189sPhase 1/21 trial
FN-1501Phase 11 trial
Active Trials
NCT03690154Terminated67Est. Feb 2022
NCT04237805Recruiting280Est. Mar 2026
RAPT Therapeutics
RAPT TherapeuticsSOUTH SAN FRANCISCO, CA
1 program
1
FLX475Phase 1/2
Bayer
BayerLEVERKUSEN, Germany
1 program
1
RDEA119Phase 1/22 trials
Active Trials
NCT00785226Completed62Est. Apr 2012
NCT00610194Completed69Est. Aug 2012
Pfizer
PfizerNEW YORK, NY
4 programs
4
ARRY-334543, EGFR/ErbB2 inhibitor; oralPhase 11 trial
ARRY-334543, EGFR/ErbB2 inhibitor; oralPhase 11 trial
ARRY-334543, EGFR/ErbB2 inhibitor; oralPhase 11 trial
PF-05212384Phase 15 trials
Active Trials
NCT00637702Completed31Est. Oct 2012
NCT00833326Completed27Est. Jul 2010
NCT00278902Completed96Est. Jun 2009
+5 more trials
Arcus Biosciences
2 programs
2
AB598Phase 11 trial
AB801Phase 11 trial
Active Trials
NCT05891171Active Not RecruitingEst. Mar 2026
NCT06120075Active Not RecruitingEst. Nov 2026
Akesobio
AkesobioChina - Zhongshan
2 programs
2
AK-104Phase 11 trial
AK-105Phase 11 trial
Active Trials
NCT03261011CompletedEst. Apr 2023
NCT03352531CompletedEst. Oct 2023
Celldex Therapeutics
2 programs
2
CDX-0158Phase 11 trial
KTN3379Phase 11 trial
Active Trials
NCT02642016Completed28Est. Jun 2019
NCT02014909Completed64Est. Jun 2017
DS
Daiichi SankyoChina - Shanghai
2 programs
2
CS-7017Phase 14 trials
DS-9606aPhase 11 trial
Active Trials
NCT01101334Completed90Est. Apr 2013
NCT00881569Completed2Est. Sep 2011
NCT00603941Terminated19Est. Dec 2011
+2 more trials
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
2 programs
2
NKTR-102Phase 11 trial
NKTR-214Phase 1
Active Trials
NCT01976143CompletedEst. Sep 2016
Astex Pharmaceuticals
Astex PharmaceuticalsUK - Cambridge
1 program
1
ASTX660Phase 1
ME Therapeutics
ME TherapeuticsNEW YORK, NY
1 program
1
Amblyomin-XPhase 11 trial
Active Trials
NCT03120130SuspendedEst. May 2022
BioCity Biopharma
1 program
1
BC3195Phase 11 trial
Active Trials
NCT06548672RecruitingEst. Jun 2027
BeOne Medicines
BeOne MedicinesCA - San Carlos
1 program
1
BGB-B3227Phase 11 trial
Active Trials
NCT06540066TerminatedEst. Dec 2025
Acrotech Biopharma
Acrotech BiopharmaNJ - East Windsor
1 program
1
BelinostatPhase 1Small Molecule1 trial
Active Trials
NCT01583777CompletedEst. Apr 2015
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
CemiplimabPhase 1Monoclonal Antibody
Providence Therapeutics
1 program
1
Cohort 1 anti-OX40Phase 11 trial
Active Trials
NCT01644968CompletedEst. Apr 2017
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
JZP815Phase 11 trial
Active Trials
NCT05557045Recruiting332Est. Apr 2028
E
1 program
1
LenvatinibPhase 1Small Molecule1 trial
Active Trials
NCT02915172Withdrawn0
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
MRTX849Phase 11 trial
Active Trials
NCT04975256Terminated7Est. Nov 2022
Novartis
NovartisBASEL, Switzerland
1 program
1
MRTX849Phase 11 trial
Active Trials
NCT04330664Completed86Est. Feb 2025
Processa Pharmaceuticals
1 program
1
PCS6422 and capecitabinePhase 11 trial
Active Trials
NCT04861987Completed23Est. Sep 2024
PTC Therapeutics
1 program
1
PTC299Phase 11 trial
Active Trials
NCT00704821Terminated76Est. Feb 2012

+3 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
PfizerPF-05212384
PfizerPF-05212384
Daiichi SankyoCS-7017
Alliance PharmaceuticalsRemeron
Merck & Co.TT-816
Chia Tai TianQing Pharmaceutical GroupTQB2858 injection
Artios PharmaART0380
Merck & Co.LY3200882
Bristol Myers SquibbBMS-986258
PfizerPF-05212384
Bristol Myers SquibbIpilimumab
Fosun PharmaSAF-189s
BayerRDEA119
Daiichi SankyoCS-7017
CASI PharmaceuticalsMKC-1

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 2,554 patients across 50 trials

NCT01925274PfizerPF-05212384

A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer

Start: Nov 2013Est. completion: Apr 201619 patients
Phase 2Terminated
NCT01420081PfizerPF-05212384

A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer

Start: Jan 2012Est. completion: Dec 201567 patients
Phase 2Terminated
NCT01101334Daiichi SankyoCS-7017

Study of Erlotinib With or Without Investigational Drug (CS-7017) in Subjects With Advanced Non-small Cell Lung Cancer

Start: Mar 2010Est. completion: Apr 201390 patients
Phase 2Completed
NCT00832520Alliance PharmaceuticalsRemeron

Phase II Study of Remeron for Cancer Patients Losing More Than 10% of Their Body Weight

Start: Nov 2008Est. completion: Jun 201113 patients
Phase 2Terminated
NCT05525455Merck & Co.TT-816

TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)

Start: Aug 2022Est. completion: Sep 20239 patients
Phase 1/2Terminated
NCT05154630Chia Tai TianQing Pharmaceutical GroupTQB2858 injection

Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors

Start: Jan 2022Est. completion: Jun 2023
Phase 1/2Terminated
NCT04657068Artios PharmaART0380

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Start: Dec 2020Est. completion: Dec 2026502 patients
Phase 1/2Recruiting
NCT04158700Merck & Co.LY3200882

A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer

Start: Dec 2019Est. completion: May 20230
Phase 1/2Withdrawn
NCT03446040Bristol Myers SquibbBMS-986258

An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Start: Mar 2018Est. completion: Aug 202492 patients
Phase 1/2Terminated
NCT02920450PfizerPF-05212384

Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)

Start: Sep 2017Est. completion: Apr 20193 patients
Phase 1/2Terminated
NCT03110107Bristol Myers SquibbIpilimumab

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors

Start: May 2017Est. completion: Apr 2024376 patients
Phase 1/2Terminated
NCT04237805Fosun PharmaSAF-189s

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Start: Nov 2016Est. completion: Mar 2026280 patients
Phase 1/2Recruiting
NCT00785226BayerRDEA119

RDEA119 and Sorafenib Combination Dose Escalation Study

Start: Nov 2008Est. completion: Apr 201262 patients
Phase 1/2Completed
NCT00603941Daiichi SankyoCS-7017

A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel

Start: Jan 2008Est. completion: Dec 201119 patients
Phase 1/2Terminated
NCT00408226CASI PharmaceuticalsMKC-1

Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung Cancer

Start: Oct 2006Est. completion: Jan 2012
Phase 1/2Completed
NCT07269145Chia Tai TianQing Pharmaceutical GroupTQB3122 Capsules

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors

Start: Jan 2026Est. completion: Dec 2026
Phase 1Recruiting
NCT07291050Chia Tai TianQing Pharmaceutical GroupTQB3217Tablets

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors

Start: Dec 2025Est. completion: Dec 2026
Phase 1Not Yet Recruiting
NCT06662760Chia Tai TianQing Pharmaceutical GroupTQB3002 Tablets

Clinical Trial of TQB3002 in Patients With Advanced Cancers

Start: Dec 2024Est. completion: Oct 2026
Phase 1Recruiting
NCT06540066BeOne MedicinesBGB-B3227

A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors

Start: Sep 2024Est. completion: Dec 2025
Phase 1Terminated
NCT06548672BioCity BiopharmaBC3195

A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer

Start: Jun 2024Est. completion: Jun 2027
Phase 1Recruiting
NCT06188624Chia Tai TianQing Pharmaceutical GroupTQB2922 for injection

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Start: Feb 2024Est. completion: Dec 2027
Phase 1Recruiting
NCT06120075Arcus BiosciencesAB801

A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies

Start: Jan 2024Est. completion: Nov 2026
Phase 1Active Not Recruiting
NCT05891171Arcus BiosciencesAB598

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Start: Oct 2023Est. completion: Mar 2026
Phase 1Active Not Recruiting
NCT05894421Chia Tai TianQing Pharmaceutical GroupTQB2223 injection+ Penpulimab Injection

TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Start: Jun 2023Est. completion: Jan 2026
Phase 1Recruiting
NCT05735496Chia Tai TianQing Pharmaceutical GroupTQB2102 injection

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Start: Mar 2023Est. completion: Jul 2027
Phase 1Active Not Recruiting
NCT05557045Jazz PharmaceuticalsJZP815

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Start: Oct 2022Est. completion: Apr 2028332 patients
Phase 1Recruiting
NCT05394675Daiichi SankyoDS-9606a

A Study of DS-9606a in Patients With Advanced Solid Tumors

Start: May 2022Est. completion: Feb 202688 patients
Phase 1Active Not Recruiting
NCT05082259Merck & Co.ASTX660

ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab

Start: Mar 2022Est. completion: Mar 202661 patients
Phase 1Recruiting
NCT05192512Chia Tai TianQing Pharmaceutical GroupTQB2928 injection

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Start: Jan 2022Est. completion: Jan 2025
Phase 1Unknown
NCT04991480Artios PharmaART4215

A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors

Start: Sep 2021Est. completion: Dec 202593 patients
Phase 1Completed
NCT05028218Chia Tai TianQing Pharmaceutical GroupTQB3824 tablets

A Clinical Study of TQB3824 in Subjects With Advanced Cancer

Start: Aug 2021Est. completion: Dec 2024
Phase 1Unknown
NCT04975256Boehringer IngelheimMRTX849

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Start: Jul 2021Est. completion: Nov 20227 patients
Phase 1Terminated
NCT04861987Processa PharmaceuticalsPCS6422 and capecitabine

A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors

Start: Jun 2021Est. completion: Sep 202423 patients
Phase 1Completed
NCT03120130ME TherapeuticsAmblyomin-X

Study of Amblyomin-X in Advanced Solid Tumor

Start: Feb 2021Est. completion: May 2022
Phase 1Suspended
NCT04648202Merck & Co.FS120

FS120 Phase 1/1b Study in Patients With Advanced Malignancies

Start: Nov 2020Est. completion: Mar 202682 patients
Phase 1Active Not Recruiting
NCT04257617Zai LabZL-1201

A Trial of ZL-1201 in Subjects With Advanced Cancer

Start: May 2020Est. completion: Jan 202337 patients
Phase 1Completed
NCT04330664NovartisMRTX849

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Start: Apr 2020Est. completion: Feb 202586 patients
Phase 1Completed
NCT03667716Bristol Myers SquibbCOM701

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Start: Sep 2018Est. completion: Jan 2024121 patients
Phase 1Completed
NCT03690154Fosun PharmaFN-1501

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Start: Jul 2018Est. completion: Feb 202267 patients
Phase 1Terminated
NCT03352531AkesobioAK-105

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors

Start: Jan 2018Est. completion: Oct 2023
Phase 1Completed
NCT03261011AkesobioAK-104

Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

Start: Oct 2017Est. completion: Apr 2023
Phase 1Completed
NCT02944864Chia Tai TianQing Pharmaceutical GroupTQ-B3395

A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics

Start: Sep 2017Est. completion: Sep 2022
Phase 1Terminated
NCT03099330Chia Tai TianQing Pharmaceutical GroupTQ-B3139

A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics

Start: Jul 2017Est. completion: Dec 2018
Phase 1Unknown
NCT03019276Chia Tai TianQing Pharmaceutical GroupTQ-B3101

A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics

Start: Jul 2017Est. completion: Dec 2018
Phase 1Unknown
NCT03192943Bristol Myers SquibbBMS-986205

A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors

Start: Jun 2017Est. completion: Dec 201811 patients
Phase 1Completed
NCT02996838Chia Tai TianQing Pharmaceutical GroupTQ-B3234

A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics

Start: May 2017Est. completion: Dec 2020
Phase 1Unknown
NCT02915172EisaiLenvatinib

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Start: Dec 20160
Phase 1Withdrawn
NCT02884726Bristol Myers SquibbBMS-986148

Phase 1 Study of Mesothelin-ADC

Start: Oct 2016Est. completion: Sep 20178 patients
Phase 1Completed
NCT02778126Eli Lilly and Company[¹⁴C]Prexasertib

A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

Start: Sep 2016Est. completion: Jul 20176 patients
Phase 1Completed
NCT02825563Chia Tai TianQing Pharmaceutical GroupAnlotinib

A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients

Start: Jun 2016Est. completion: Aug 2018
Phase 1Completed

Related Jobs in Oncology

Cell Therapy Account Manager（北陸）

Gilead Sciences
Japan - Tokyo
Just now

Leo Cancer Care: Senior In-House Counsel/General Counsel

Leo Cancer Care
Middleton, Wisconsin
1h ago

Summer Intern - Computational Chemistry & Artificial Intelligence

Arvinas
Remote
3h ago

Executive Director, I.T.- Head of Security Architecture, Engineering, and Delivery

Gilead Sciences
United States - California - Foster City
17h ago
$281K - $364K/yr

Sr Research Associate, Analytical Operations

Gilead Sciences
United States - California - Oceanside
17h ago
$86K - $112K/yr

Associate Director, Insights & Analytics Platform Technology Lead

Gilead Sciences
United States - California - Foster City
17h ago
$196K - $253K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
9 actively recruiting trials targeting 2,554 patients
30 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)